Johannes Andel
About
Johannes Andel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Johannes Andel has authored 30 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Johannes Andel's work include Cancer Treatment and Pharmacology (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). Johannes Andel is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). Johannes Andel collaborates with scholars based in Austria, Germany and Switzerland. Johannes Andel's co-authors include Richard Greil, Andreas Petzer, Sonja Burgstaller, Reinhard Ziebermayr, Hans‐Joachim Schmoll, W. C. J. Hop, Jorge Riera‐Knorrenschild, Hendrik Kroening, Werner Scheithauer and Burghardt Wittig and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Johannes Andel
29 papers receiving 413 citations
Peers
Johannes Andel
Preeti Narayan United States
Jennifer McDevitt United States
Tetsuhiro Nakano Japan
David Pérez-Callejo Spain
Erin E. Karski United States
Wenxiao Jia China
Jian You China
Mohamed M. Kahila United States
Debbie Robbrecht Netherlands
Citations per year, relative to Johannes Andel Johannes Andel (= 1×)
peers
Preeti Narayan
Countries citing papers authored by Johannes Andel
Since
Specialization
Citations
This map shows the geographic impact of Johannes Andel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johannes Andel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johannes Andel more than expected).
Fields of papers citing papers by Johannes Andel
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Johannes Andel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johannes Andel. The network helps show where Johannes Andel may publish in the future.
Co-authorship network of co-authors of Johannes Andel
This figure shows the co-authorship network connecting the top 25 collaborators of Johannes Andel. A scholar is included among the top collaborators of Johannes Andel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johannes Andel. Johannes Andel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gampenrieder, Simon Peter, Gabriel Rinnerthaler, Christoph Tinchon, et al.. (2022). Abstract P1-21-08: Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry. Cancer Research. 82(4_Supplement). P1–21.
2.
Magnes, Teresa, Thomas Melchardt, Lukas Weiß, et al.. (2021). Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone. Wiener klinische Wochenschrift. 133(21-22). 1131–1136.
3.
Gampenrieder, Simon Peter, Gabriel Rinnerthaler, Christoph Tinchon, et al.. (2021). Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. Breast Cancer Research. 23(1). 112–112.
4.
Rinnerthaler, Gabriel, Simon Peter Gampenrieder, Andreas Petzer, et al.. (2021). Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6). Therapeutic Advances in Medical Oncology. 13. 4277454333–4277454333.
5.
Vormittag, Laurenz, Leopold Öhler, Birgit Grünberger, et al.. (2020). REGO-ACT: assessment of physical activity during treatment with regorafenib for metastatic colorectal cancer. Wiener klinische Wochenschrift. 132(15-16). 423–430.
6.
Huemer, Florian, Lukas Weiß, Peter Regitnig, et al.. (2020). Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry. Journal of Clinical Medicine. 9(4). 935–935.
7.
Ludwig, Heinz, Niklas Zojer, Johannes Andel, et al.. (2019). Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02). Blood. 134(Supplement_1). 696–696.
8.
Steurer, Michael, Marco Montillo, Lydia Scarfò, et al.. (2019). Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 104(10). 2053–2060.
9.
Lechner, Daniel, Richard Greil, Bernd Hartmann, et al.. (2018). Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real World Data from an Ongoing, National, Multi-Center, Non-Interventional Study. Blood. 132(Supplement 1). 2018–2018.
10.
Steger, Guenther G., Edgar Petru, Ferdinand Haslbauer, et al.. (2016). Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: a prospective, multicenter non-interventional study. Annals of Oncology. 27. vi74–vi74.
11.
Fridrik, Michael, Ulrich Jaeger, Andreas Petzer, et al.. (2016). Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma. European Journal of Cancer. 58. 112–121.
12.
Schmoll, Hans‐Joachim, Jorge Riera‐Knorrenschild, Hans‐Georg Kopp, et al.. (2015). Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: A subgroup with improved overall survival.. Journal of Clinical Oncology. 33(3_suppl). 680–680.
13.
Schmoll, Hans‐Joachim, Burghardt Wittig, Dirk Arnold, et al.. (2014). Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. Journal of Cancer Research and Clinical Oncology. 140(9). 1615–1624.
14.
Schmoll, Hans‐Joachim, Jorge Riera‐Knorrenschild, Hendrik Kroening, et al.. (2013). Updated Results of the Randomized Phase 2 Impact Trial: Maintenance with TLR-9 Agonist Mgn1703 Vs Placebo in Patients with Metastatic Colorectal Carcinoma (MCRC). Annals of Oncology. 24. iv16–iv16.
15.
Fiegl, Michael, Florian Falkner, Michael Steurer, et al.. (2011). Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. Annals of Hematology. 90(9). 1083–1091.
16.
Fridrik, Michael, Andreas Petzer, Felix Keil, et al.. (2011). Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial. Blood. 118(21). 2676–2676.
17.
Mlineritsch, Brigitte, Johannes Andel, Michael Fridrik, et al.. (2009). Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer. Oncology Research and Treatment. 32(1-2). 18–24.
18.
Petru, Edgar, Johannes Andel, Günther Steger, et al.. (2008). Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy. Wiener Medizinische Wochenschrift. 158(5-6). 169–173.
19.
Boon, Mathilde E., et al.. (1981). Secreting peritoneal mesothelioma. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 392(1). 33–44.
20.
Byar, David P., et al.. (1978). Results of a E.O.R.T.C. randomized trial of cyclophosphamide and radiotherapy in inoperable lung cancer: Prognostic factors and treatment results. European Journal of Cancer (1965). 14(9). 919–930.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Preeti Narayan Breakdown of academic impact, for papers by Jennifer McDevitt Breakdown of academic impact, for papers by Tetsuhiro Nakano Breakdown of academic impact, for papers by David Pérez-Callejo Breakdown of academic impact, for papers by Erin E. Karski Breakdown of academic impact, for papers by Wenxiao Jia Breakdown of academic impact, for papers by Jian You Breakdown of academic impact, for papers by Mohamed M. Kahila Breakdown of academic impact, for papers by Debbie Robbrecht